<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987112</url>
  </required_header>
  <id_info>
    <org_study_id>CAN1012</org_study_id>
    <nct_id>NCT04987112</nct_id>
  </id_info>
  <brief_title>Intratumoral CAN1012 in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1, Dose Escalation, Open-Label Study of Intratumoral CAN1012 in Subjects With Unresectable or Metastatic Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CanWell Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CanWell Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors&#xD;
      who are not candidates for standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, first-in-human, single-arm, multicenter, dose escalation study&#xD;
      of IT CAN1012 in subjects with advanced solid tumors who are not candidates for standard&#xD;
      therapy.&#xD;
&#xD;
      Subjects will be enrolled in cohorts of 3 at each dose level using a 3+3 dose escalation&#xD;
      design Approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>12 months</time_frame>
    <description>Safety and tolerability as determined by assessment of dose limiting toxicities and the maximum tolerated dose or maximal assessed dose per protocol of CAN1012 with cancers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>12 months</time_frame>
    <description>To determine a recommended phase 2 dose of CAN1012 for further development by evaluating number of patients with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>12 months</time_frame>
    <description>Determine the maximum tolerated dose by assessing the Incidence of Dose Limiting Toxicities (DLTs), treatment emergent and treatment related adverse events (assessed by CTCAE v5.0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK characterization - Cmax</measure>
    <time_frame>12 months</time_frame>
    <description>Maximum observed plasma and tumor concentration of CAN1012 after IT administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK characterization - tmax</measure>
    <time_frame>12 months</time_frame>
    <description>Time to reach maximum plasma and tumor concentration of CAN1012 after IT administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor size in injected lesions and non-injected lesions</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in tumor size using computed tomography (CT) scan or magnetic resonance imaging (MRI) scan assessment based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>CAN1012 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAN1012 intratumoral injection given alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAN1012</intervention_name>
    <description>CAN1012 IT injection (once every 4 weeks)</description>
    <arm_group_label>CAN1012 single agent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able and willing to provide written informed consent and willing to comply with the&#xD;
             study's requirements.&#xD;
&#xD;
          2. Male or female age &gt;18 years at screening.&#xD;
&#xD;
          3. Metastatic or locally advanced solid tumor that has progressed on, is refractory to,&#xD;
             or for which there is no efficacious standard of care therapy.&#xD;
&#xD;
          4. Demonstrate adequate organ function as defined below. All screening laboratory&#xD;
             assessments should be performed within 14 days of treatment initiation and include the&#xD;
             following:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) ≥1.5 × 109/L； Platelets ≥100 × 109/L；Hemoglobin&#xD;
                  ≥9 g/dL or ≥5.6 mmol/L&#xD;
&#xD;
               2. Measured or calculated creatinine clearance (CrCl) ≥ 60 mL/min&#xD;
&#xD;
               3. Total bilirubin ≤1.5 × ULN OR direct bilirubin ≤ULN for subjects with total&#xD;
                  bilirubin levels &gt; 1.5× ULN； Aspartate aminotransferase (AST) and alanine&#xD;
                  aminotransferase (ALT) ≤ 2.5 × ULN OR ≤5 × ULN for subjects with liver&#xD;
                  metastases.&#xD;
&#xD;
          5. Performance status of 0 or 1 on the ECOG Performance Scale.&#xD;
&#xD;
          6. Life expectancy &gt;12 weeks at Baseline.&#xD;
&#xD;
          7. Women of childbearing potential must have negative serum pregnancy test within 3 days&#xD;
             prior to receiving the first study drug administration.&#xD;
&#xD;
          8. For women of childbearing potential, must be willing to use an adequate method of&#xD;
             contraception from 30 days prior to the first study drug administration and 120 days&#xD;
             following last day of study drug administration.&#xD;
&#xD;
          9. Male subjects of childbearing potential must be surgically sterile or must agree to&#xD;
             use adequate method of contraception during the study and at least 120 days following&#xD;
             the last day of study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received prior TLR7/8 agonists (excluding topical agents).&#xD;
&#xD;
          2. Has untreated or uncontrolled central nervous system (CNS) involvement.&#xD;
&#xD;
          3. Will receive concurrent chemotherapy, immunotherapy, biologic, hormonal therapy, or&#xD;
             other therapies for cancer.&#xD;
&#xD;
          4. Received systemic interferon alfa (IFNα) prior to enrollment.&#xD;
&#xD;
          5. Unresolved toxicities from prior therapy, defined as having not resolved to CTCAE v5.0&#xD;
             Grade 0 or 1, with exception of endocrinopathies from prior therapy, alopecia, and&#xD;
             vitiligo.&#xD;
&#xD;
          6. Treatment with systemic corticosteroids.&#xD;
&#xD;
          7. Concomitant or planned use of sensitive substrates of major cytochrome P450 enzymes.&#xD;
&#xD;
          8. Has an active infection requiring systemic therapy.&#xD;
&#xD;
          9. Has known active infection with the human immunodeficiency virus,&#xD;
&#xD;
         10. Unstable/inadequate cardiac function.&#xD;
&#xD;
         11. Uncontrolled concurrent illness.&#xD;
&#xD;
         12. A history of interstitial lung disease.&#xD;
&#xD;
         13. A history of coagulopathy resulting in uncontrolled bleeding or other bleeding&#xD;
             disorders.&#xD;
&#xD;
         14. Participated in a clinical study of an investigational agent within 30 days of&#xD;
             screening.&#xD;
&#xD;
         15. Has known psychiatric, substance abuse, or other disorders that would interfere with&#xD;
             cooperation with the requirements of the study in the opinion of the investigator.&#xD;
&#xD;
         16. Is pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles Li, doctor</last_name>
    <phone>1-858-229-5839</phone>
    <email>charlesli@canwellbiotech.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

